Somewhat Positive Press Coverage Somewhat Unlikely to Affect Stellar Biotechnologies (NASDAQ:SBOT) Share Price
Press coverage about Stellar Biotechnologies (NASDAQ:SBOT) has trended somewhat positive recently, Accern Sentiment reports. Accern ranks the sentiment of media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Stellar Biotechnologies earned a news sentiment score of 0.18 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 45.4716885184854 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
These are some of the news headlines that may have effected Accern Sentiment Analysis’s scoring:
- Bargain Hunter Investor Update on Stellar Biotechnologies, Inc … – FLBC News (flbcnews.com)
- Stellar Biotechnologies Inc (SBOT) Moves -0.78% – Evergreen Caller (evergreencaller.com)
- Focusing the Lens on Stellar Biotechnologies Inc (SBOT) Shares: Technical Update – Stock Press Daily (stockpressdaily.com)
- Primed for Breakout or Bust? A look at Stellar Biotechnologies, Inc. (:SBOT) – FLBC News (flbcnews.com)
Stellar Biotechnologies (NASDAQ SBOT) opened at 1.27 on Wednesday. Stellar Biotechnologies has a 1-year low of $1.05 and a 1-year high of $3.10. The stock has a 50 day moving average price of $1.30 and a 200-day moving average price of $1.47. The company’s market capitalization is $12.87 million.
Stellar Biotechnologies (NASDAQ:SBOT) last issued its earnings results on Tuesday, May 9th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.15) by $0.04. Stellar Biotechnologies had a negative net margin of 774.21% and a negative return on equity of 50.56%. The business had revenue of $0.06 million during the quarter, compared to the consensus estimate of $0.33 million. Equities analysts predict that Stellar Biotechnologies will post ($0.47) earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: This report was first posted by Daily Political and is owned by of Daily Political. If you are accessing this report on another website, it was stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this report can be accessed at https://www.dailypolitical.com/2017/08/09/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-stellar-biotechnologies-nasdaqsbot-share-price.html.
About Stellar Biotechnologies
Stellar Biotechnologies, Inc is a biotechnology company. The Company is engaged in the aquaculture, research and development, manufacture and commercialization of Keyhole Limpet Hemocyanin (KLH). KLH is an immune-stimulating protein. KLH can be used as an active pharmaceutical ingredient (API) and combined with a disease-targeting agent to create immunotherapies for the treatment of a range of diseases.
Receive News & Ratings for Stellar Biotechnologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stellar Biotechnologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.